OTCBB:LIXT

Lixte Biotechnology Holdings Stock Insider Trading

Healthcare > Biotechnology

Buy LIXT

*Your capital is at risk

$7.21

+0 (+0%)

At Close: Jul 13, 2026

Lixte Biotechnology Holdings Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 42.83. In total, the insiders bought 2.41M and sold 500K LIXT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	42.83
● Buy	2.41M shares
● Sell	500K shares
94% Buy Activity Moderate Negative Correlation
Buy Signal Medium Confidence Jul 01, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 42.83. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (94% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 01, 2026 Buy	Common Stock J-Other	Travaglini John Francis	Director	0 Value: $0
Jul 01, 2026 Buy	Common Stock A-Award	Primus Guy Warren Director	Director	15 000 Value: $115.1K
Jul 01, 2026 Buy	Common Stock A-Award	Pursglove Geordan Garrett CEO And Chairman Of The Board	CEO / President	350 000 Value: $2.68M
Jul 01, 2026 Buy	Common Stock A-Award	Sawyer Jason David Director	Director	40 000 Value: $306.8K
Jul 01, 2026 Buy	Common Stock A-Award	Felix Lourdes Director	Director	30 000 Value: $230.1K
Jul 01, 2026 Buy	Common Stock A-Award	Stazzone Peter Chief Financial Officer	C-Suite Officer	50 000 Value: $383.5K
Jul 01, 2026 Buy	Common Stock A-Award	Holloway Michael Andrew Director	Director	15 000 Value: $115.1K
May 29, 2026 Buy	Common Stock A-Award	Porter Stuart D Director	Director	25 000 Value: $156.3K
May 29, 2026 Buy	Common Stock J-Other	Porter Stuart D	Director	0 Value: $0
Apr 15, 2026 Sell	Stock Option (right to buy) D-Return	Primus Guy Warren Director	Director	25 000 Value: $101.3K
Apr 15, 2026 Buy	Common Stock A-Award	Primus Guy Warren Director	Director	25 000 Value: $77.8K
Apr 15, 2026 Sell	Options to Purchase Common Stock D-Return	Sawyer Jason David Director	Director	25 000 Value: $89.8K
Apr 15, 2026 Sell	Stock Option (right to buy) D-Return	Felix Lourdes Director	Director	25 000 Value: $101.3K
Apr 15, 2026 Buy	Common Stock A-Award	Pursglove Geordan Garrett CEO And Chairman Of The Board	CEO / President	350 000 Value: $1.09M
Apr 15, 2026 Sell	Options to Purchase Common Stock D-Return	Pursglove Geordan Garrett CEO And Chairman Of The Board	CEO / President	350 000 Value: $990.5K
Apr 15, 2026 Buy	Common Stock A-Award	Stazzone Peter Chief Financial Officer	C-Suite Officer	50 000 Value: $155.5K
Apr 15, 2026 Sell	Options to Purchase Common Stock D-Return	Stazzone Peter Chief Financial Officer	C-Suite Officer	50 000 Value: $222.5K
Apr 15, 2026 Buy	Common Stock A-Award	Sawyer Jason David Director	Director	25 000 Value: $77.8K
Apr 15, 2026 Buy	Common Stock A-Award	Felix Lourdes Director	Director	25 000 Value: $77.8K
Apr 15, 2026 Buy	Common Stock A-Award	Holloway Michael Andrew Director	Director	25 000 Value: $77.8K
Apr 15, 2026 Sell	Options to Purchase Common Stock D-Return	Holloway Michael Andrew Director	Director	25 000 Value: $89.8K
Dec 24, 2025 Buy	Stock Option (right to buy) A-Award	Primus Guy Warren Director	Director	25 000 Value: $101.3K
Dec 24, 2025 Buy	Stock Option (right to buy) A-Award	Felix Lourdes Director	Director	25 000 Value: $101.3K
Sep 01, 2025 Buy	Common Stock J-Other	Primus Guy Warren	Director	0 Value: $0
Sep 01, 2025 Buy	Common Stock J-Other	Primus Guy Warren	Director	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at var...

Read Full Profile Here